a dedicated section for students, CEOs and high performers
However, in addition to reports of increased risk of hemorrhage and heart failure with supplemental vitamin E in several randomized controlled studies (see Cardiovascular disease), a meta-analysis by Miller et al
2010 Jun 28;16(24):297890
This phosphorylation inhibits acetyl-CoA carboxylase, which in turn lowers the concentration of malonyl-CoA
The new research raises hope that GLP-1 drugs could serve as a strategy for breast cancer prevention, especially among higher-risk females with overweight and obesity
Typical PA requirements include: Confirmed diagnosis of type 2 diabetes or obesity Documented BMI (often 30 or 27 with comorbidities) Failed trials of other medications Lifestyle modification attempts Recent A1C lab values (for diabetes) Documentation Must Include Height and weight with calculated BMI Diagnosis supporting medical necessity Treatment plan Follow-up and monitoring plan Compliance & Audit Risk GLP-1 medications are a high-risk audit target due to: Rapid growth in utilization High drug cost Off-label prescribing Weight-loss demand Common audit issues: Incorrect diagnosis codes Missing BMI documentation Lack of medical necessity Billing weight-loss drugs to Medicare Inappropriate use of unclassified J-codes Medicare Coverage Rules Medicare Part D generally does not cover weight-loss drugs , even if FDA-approved for obesity
